A landmark comprehensive analysis showed sodium‑glucose cotransporter‑2 (SGLT2) inhibitors confer kidney and cardiovascular benefits across a broad range of glomerular filtration rates and albuminuria levels. The study pooled contemporary evidence to support routine SGLT2 use in patients with type 2 diabetes, chronic kidney disease and heart failure regardless of baseline eGFR within studied ranges. Authors concluded that the class’s renoprotective and cardioprotective effects are consistent across subgroups, reinforcing guideline recommendations and informing clinicians on prescribing SGLT2s to diverse renal populations.